INO INOVIO PHARMACEUTICALS, INC.

Nasdaq Pharmaceutical Preparations DE CIK: 0001055726
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

Inovio is in severe financial distress with zero revenue, significant accumulated operating losses, and a debt burden ($62.8M) exceeding total assets ($49.8M). With negative operating cash flow of -$21.6M annually and only $26.3M in cash, the company has approximately 14 months of runway before capital depletion at current burn rate, making it unsuitable for fundamental investors.

Strengths

  • + Retains $26.3M in cash providing near-term liquidity buffer
  • + Operating losses moderating slightly year-over-year (EPS loss improvement)
  • + Insider trading activity suggests management engagement in company direction

Risks

  • ! Zero revenue with -70% YoY decline indicates failed commercialization or pre-revenue stage
  • ! Liabilities ($43.7M) nearly consume all assets ($49.8M) with minimal equity cushion of $6.1M
  • ! Debt/Equity ratio of 10.34x and interest coverage of -123.4x indicate inability to service debt from operations
  • ! Negative operating cash flow of -$21.6M annually with ~14 months cash runway at current burn rate
  • ! Balance sheet insolvency risk requiring debt restructuring, dilutive equity financing, or asset liquidation

Key Metrics to Watch

Financial Metrics

Revenue
0.0
Net Income
-19.7M
EPS (Diluted)
$-0.28
Free Cash Flow
-21.6M
Total Assets
49.8M
Cash
26.3M

Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE -324.4%
ROA -39.5%
FCF Margin N/A

Balance Sheet & Liquidity

Current Ratio
1.04x
Quick Ratio
1.04x
Debt/Equity
10.34x
Debt/Assets
87.8%
Interest Coverage
-123.43x
Long-term Debt
62.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-14T08:36:17.997769 | Data as of: 2026-03-31 | Powered by Claude AI